Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Kanters, Tim A ^a,b   Hoogenboom Plug, Iris ^b   Rutten Van Mölken, Maureen Pmh ^a   Redekop, W Ken ^a   Van Der Ploeg, Ans T ^b   Hakkaart, Leona ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; Enzyme replacement therapy; Infants; Pompe disease; Quality adjusted lifeyears

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE; GAA PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCHOOL CHILD; SURVIVAL; TEACHING; YOUNG ADULT; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; GLYCOGEN STORAGE DISEASE TYPE II; INFANT; NEWBORN; PATHOPHYSIOLOGY;

ALPHA-GLUCOSIDASES; COST-BENEFIT ANALYSIS; DRUG COSTS; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; INFANT, NEWBORN; PATIENT SIMULATION; QUALITY OF LIFE;

EID: 84901719619     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-75     Document Type: Article

References (26)

1. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Schey C, Milanova T, Hutchings A, Orphanet J Rare Dis 2011 6 62 10.1186/1750-1172-6-62 21951518
2. Evidence and values: requirements for public reimbursement of drugs for rare diseases-a case study in oncology. Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, MacLeod S, Can J Clin Pharmacol 2009 16 273 e281 19439771
3. Coverage with evidence development: an examination of conceptual and policy issues. Hutton J, Trueman P, Henshall C, Int J Technol Assess Health Care 2007 23 425 432 17937829
4. Access mechanisms for orphan drugs: a comparative study of selected European countries. Garau M, Mestre-Ferrandiz J, Off Health Econ 2009 52 1 30
5. Pompe disease in infants and children. Kishnani PS, Howell RR, J Pediatr 2004 144 35 S43 10.1016/j.jpeds.2004.01.053 15126982
6. Pompe's disease. Van der Ploeg AT, Reuser AJJ, Lancet 2008 372 1342 1353 10.1016/S0140-6736(08)61555-X 18929906
7. Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counselling. Ausems MGEM, Verbiest J, Hermans MMP, Kroos MA, Beemer FA, Wokke JHJ, Sandkuijl LA, Reuser AJJ, Van der Ploeg AT, Eur J Hum Genet 1999 7 713 716 10.1038/sj.ejhg.5200367 10482961
8. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Van den Hout HMP, Hop W, Van Diggelen OP, Smeitink JAM, Smit GPA, Bakker HD, Loonen MCB, de Klerk JBC, Reuser AJJ, Van der Ploeg AT, Pediatrics 2003 112 332 340 10.1542/peds.112.2.332 12897283
9. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, J Pediatr 2006 148 671 676 10.1016/j.jpeds.2005.11.033 16737883
10. Recombinant human acid-glucosidase: major clinical benefits in infantile-onset Pompe disease. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Neurology 2007 68 99 109 10.1212/01.wnl.0000251268.41188.04 17151339
11. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, Bauer MS, Pediatr Res 2009 66 329 335 10.1203/PDR.0b013e3181b24e94 19542901
12. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ, Clin Ther 2010 32 1651 1661 10.1016/j.clinthera.2010.08.006 20974323
13. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL, Pivnick EK, Ottinger C, Robinson PH, Loo JA, Smitka M, Jardine P, Tato L, Chabrol B, McCandless S, Kimura S, Mehta L, Bali D, Skrinar A, Morgan C, Rangashari L, Corzo D, Kishnani PS, Genet Med 2009 11 210 219 10.1097/GIM.0b013e31819d0996 19287243
14. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data inconsistencies, limitations, and a practical guide. Latimer NR, Med Decis Making 2013 33 743 754 10.1177/0272989X12472398 23341049
15. Statistics Netherlands, Life Expectancy; age and Gender 2011 Retrieved 04/10, 2013, from http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA= 37450&D1=0&D2=a&D3=0-91&D4=l&HDR=T,G1&STB=G2,G3&VW=T
16. EuroQol: a new facility for the measurement of health-related quality of life. EuroQol Group, Health Policy 1990 16 199 208 10109801
17. The Dutch tariff: results and arguments for an effective design for national EQ5D valuation studies. Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV, Health Econ 2006 15 1121 1132 10.1002/hec.1124 16786549
18. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH, Manual for Costing Studies, Methods and Standard Unit Costs for Economic Evaluations in Health Care Amstelveen, the Netherlands: College voor Zorgverzekeringen 2004
19. Burden of illness of Pompe disease in patients only receiving supportive care. Kanters TA, Hagemans MLC, Van der Beek NAME, Rutten FFH, Van der Ploeg AT, Hakkaart L, J Inherit Metab Dis 2011 34 1045 1052 10.1007/s10545-011-9320-x 21499718
20. College voor Zorgverzekeringen, Pharmacotherapeutic Compass Diemen, the Netherlands: College voor Zorgverzekeringen 2009
21. Hoogendoorn EJI, Feenstra TL, Rutten-van Molken M, Inventarisation Health Care Usage and Costs of Asthma and COPD in the Netherlands Bilthoven, the Netherlands: Rijksinstituut voor Volksgezondheid en Milieu 2005
22. College voor Zorgverzekeringen, Guidelines for Pharmacoeconomic Research, Updated Version Diemen, the Netherlands: College voor Zorgverzekeringen 2006
23. Challenges in health state valuation in paediatric economic evaluation. Ungar WJ, Pharmacoeconomics 2011 29 641 652 10.2165/11591570-000000000-00000 21604821
24. Assessing the economic challenges posed by orphan drugs. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J, Int J Technol Assess Health Care 2007 23 36 42 17234015
25. Orphan drugs and the NHS: should we value rarity? McCabe C, Claxton K, Tsuchiya A, BMJ 2005 331 1016 1019 10.1136/bmj.331.7523.1016 16254305
26. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS, BMJ 2010 341 4715 10.1136/bmj.c4715 20861122